Akeso, Inc. ((HK:9926)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Akeso, Inc. has announced a new clinical study titled ‘A Single Arm, Multi-center, Phase II Study of AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC) Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment.’ The study aims to evaluate the efficacy of AK112 in treating NSCLC patients who have not responded to previous TKI therapies, highlighting its potential significance in advancing cancer treatment options.
The intervention being tested is AK112, a drug designed to be administered as a monotherapy. Its purpose is to provide a new treatment avenue for patients with specific genomic alterations in non-squamous NSCLC who have exhausted other options.
This is an interventional study with a single-group assignment. There is no allocation or masking involved, and the primary purpose is treatment-focused. This straightforward design allows for a clear assessment of AK112’s impact on the targeted patient group.
The study is not yet recruiting, with the initial submission date set for August 14, 2025, and the last update on September 3, 2025. These dates are crucial as they mark the timeline for potential recruitment and subsequent data collection phases.
The announcement of this study could influence Akeso’s stock performance positively, as successful outcomes may enhance the company’s position in the oncology market. Investors will likely monitor this development closely, especially considering the competitive landscape in cancer therapeutics.
The study is ongoing, with further details available on the ClinicalTrials portal.